Recombinant modified vaccinia virus ancara (MVA) phyrovirus vaccine

摘要

Problem to be solved: to provide an improved phyrovirus vaccine including a recombinant modified vaccinia virus (antiviral) vaccine (MVA) vaccine for a phyrovirus infection and related products, methods of production and use.The present invention relates to a genetically modified (recombinant) MVA and an FPV vector containing at least one heterologous nucleotide sequence encoding an antigen determinant of Marburg virus (Marv) or Ebola virus glycoprotein.In particular, the present invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40.The present invention also relates to MVA and genetically modified (recombinant) FPV products suitable for inducing protective immune responses to the subject, methods and uses, and prime boost medication programs.Fig. 8B